IL-9 Antibody

ELISA, WB, Neutralization Assay

IL-9 antibody is stable for at least 2 years from date of receipt at -20˚ C. The reconstituted antibody is stable for at least two weeks at 2-8˚ C. Frozen aliquots are stable for at least 6 months when stored at -20˚ C. Avoid repeated freeze-thaw cycles.

IL-9 is a cytokine preferentially produced by T helper type 2 lymphocytes and active on various cell types such as T and B lymphocytes, mast cells and haemopoietic progenitors; but no effect of this cytokine has been reported so far on mononuclear phagocytes. IL-9 stimulates cell proliferation and prevents apoptosis. The IL-9 receptor (IL 9R) belongs to the haemopoietic receptor superfamily and its signal transduction involves mainly the (JAK/STAT) pathway. Some studies have implicated IL-9 as an important cytokine in a number of Th2 cytokine mediated pathologies, in particular asthma

None

Anti-mIL-9 specific antibody was purified by affinity chromatography employing immobilized mIL-9 matrix.

Neutralization:
To yield one-half maximal inhibition [ND50] of the biological activity of mIL-9 (0.30 ng/mL), a concentration of 0.006 - 0.012 μ g/mL of this antibody is required.
ELISA:
To detect mIL-9 by direct ELISA (using 100 μ L/well antibody solution) a concentration of at least 0.5 μ g/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant mIL-9.
Sandwich:
To detect mIL-9 by sandwich ELISA (using 100 μ L/well antibody solution) a concentration of 0.5 - 2.0 μ g/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with our Biotinylated Anti-Murine IL-9 (XP-5201Bt) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant mIL-9.
Western Blot:
To detect mIL-9 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μ g/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant mIL-9 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.

Polyclonal

Mus musculus

Centrifuge vial prior to opening.